

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM769264

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Pfizer Inc.		08/16/2022	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Antares Pharma, Inc.		
<b>Street Address:</b>	100 Princeton South, Suite 300		
<b>City:</b>	Ewing		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	08628		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	88752697	NAXREDI	
<b>Serial Number:</b>	88752698	NAXREDY	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6509385200		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	650-988-8500		
<b>Email:</b>	trademarks@fenwick.com		
<b>Correspondent Name:</b>	Karen A. Webb, Fenwick & West LLP		
<b>Address Line 1:</b>	801 California Street		
<b>Address Line 2:</b>	Silicon Valley Center		
<b>Address Line 4:</b>	Mountain View, CALIFORNIA 94041		
<b>ATTORNEY DOCKET NUMBER:</b>	38574-00101		
<b>NAME OF SUBMITTER:</b>	Karen Webb		
<b>SIGNATURE:</b>	/kaw/		
<b>DATE SIGNED:</b>	11/21/2022		
<b>Total Attachments: 1</b>			
source=Pfizer Antares Confirmation of Trademark Assignment#page1.tif			

CH \$65.00 88752697

**CONFIRMATION OF TRADEMARK ASSIGNMENT**

This Confirmation of Trademark Assignment ("*Assignment*") is entered into by and between Pfizer Inc., a Delaware corporation with a place of business at 235 East 42nd Street, New York, New York 10017 ("*Assignor*"), and Antares Pharma, Inc., a company incorporated under the laws of the State of Delaware and having its principal place of business at 100 Princeton South, Suite 300, Ewing, New Jersey 08628 ("*Assignee*"). Assignor and Assignee, jointly, referred to herein as the "*Parties*."

**WHEREAS**, Assignor is the owner of trademarks, NAXREDY, U.S. App. No. 88752698 and NAXREDI, U.S. App. No. 88752697, filing dates January 9, 2020 ("*the Naxredy Marks*").

**WHEREAS**, pursuant to a prior Second Amendment to the Development Agreement, ("*Second Amendment*") effective August 10, 2022 ("*Effective Date*"), by and among Assignor and Assignee, certain intellectual property rights, including without limitation all legal rights, title and interest in and to the Naxredy Marks, were assigned to Assignee.

**NOW, THEREFORE**, this confirms that in consideration of the promises and undertakings set forth in the Second Amendment, and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignor assigned and transferred unto Assignee all legal rights, title and interest in and to the Naxredy Marks and all the legal rights, claims and privileges pertaining to the Naxredy Marks, including without limitation, the applications pertaining thereto, common law rights, together with the goodwill of the business associated with and symbolized by the Naxredy Marks, and that portion of the business which is ongoing and existing to which the Naxredy Marks pertain, and the right to sue and recover damages for past, present and future infringements thereof and to stand in the place of Assignor in all matters related thereto.

**IN WITNESS WHEREOF**, Assignor and Assignee have caused this Assignment to be made as of the Effective Date referenced above.

Pfizer Inc.


DocuSigned by:

*Lisa Skeens*

9D692FF84AD94C7

By: \_\_\_\_\_  
Name: Lisa Skeens  
Title: VP GRA CMC and Hospital  
Date: August 16, 2022

Antares Pharma, Inc.

By:   
Name: MARK SNYDER  
Title: SVP & General Counsel  
Date: 8/16/2022